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There are several important questions in determining ART initiation 
criteria, including what is best for treating the HIV-positive individual, 
what is best for HIV and tuberculosis (TB) prevention at the population 
level, and the costs of the different options for initiating ART. While 
there is not yet enough evidence to confidently change policy to recom-
mend universal ART for all HIV-positive individuals, there are certainly 
enough data to support the implementation and evaluation of ‘test-
and-treat’ pilot programmes.
WHAT IS BEST FOR TREATING THE HIV-POSITIVE 
INDIVIDUAL?
Clinical trials have shown definitively that a CD4 threshold of 350 cells/
µl for initiating ART results in lower morbidity and mortality than 200 
cells/µl.1,2 However, observational data on whether patients with HIV 
will benefit from initiating at a higher CD4 count are less clear. 
Researchers from the North American NA-ACCORD cohort (including 
over 17 500 patients) found a nearly two times increased risk of death 
in patients who deferred ART to below 500 cells/µl.3 This study is cited 
in US treatment guidelines that provide for early treatment. However, 
the study’s statistical methods have been criticised.4,5 Other evidence 
comes from the HIV-CAUSAL collaboration, which includes nearly 
21 000 patients in Europe and America, including the NA-ACCORD pa-
tients. In this study no mortality benefit was observed for patients who 
started ART with a CD4 count above 500 cells/µl compared with those 
who started at 350 cells/µl. However, AIDS-defining illnesses were sig-
nificantly more likely among patients who started treatment at lower 
CD4 counts.6
These studies do not offer conclusive evidence that initiating ART 
early (>500 cells/µl) will benefit patients. Both NA-ACCORD and HIV- 
CAUSAL are observational studies and subject to methodological limi-
tations. The long-term side-effects of ART and the possible effect of 
treatment fatigue on adherence might mitigate against early initiation. 
Furthermore, participants in these studies were less likely to use sub-
optimal drugs, such as stavudine, that are prevalent in many resource-
limited settings.
It is hoped that two ongoing clinical trials will answer once and for all 
whether early treatment is beneficial. The Strategic Timing of Antiret-
roviral Treatment (START) trial is recruiting 4 000 volunteers. Patients 
with CD4 counts >500 cells/µl are randomised to either initiate im-
mediately or defer to 350 cells/µl.7 This international trial currently only 
has one site in sub-Saharan Africa, the Desmond Tutu HIV Centre at the 
University of Cape Town (UCT). START is due to complete in 2015, and 
clinicians in Cape Town should encourage their patients with high CD4 
counts to consider enrolling at the UCT site.
In addition, the ANRS 12136 trial in Côte d’Ivoire is due to complete 
in 2013. The trial objective is to compare the benefits and risks of ini-
tiating ART according to the WHO guidelines versus the benefits and 
risks of initiating ART immediately among HIV-positive adults with CD4 
counts >350 cells/µl.8
WHAT IS BEST FOR HIV AND TB PREVENTION AT THE 
POPULATION LEVEL?
Several observational studies show that there is a strong correlation 
between reduced HIV incidence and either increased ART coverage or 
lower viral loads in the community. In San Francisco, new HIV diag-
noses decreased along with mean community viral load from 2004 to 
2008.9 In Taiwan, there was a more than 50% decrease in HIV infections 
ascertained by community surveillance after the introduction of free 
ART.10 In British Columbia from 1996 to 2009, the number of people 
receiving ART increased from 837 to 5 413, while the number of new 
HIV diagnoses fell over 50% from 702 to 338 per year.11
Because of the possibility of confounding factors, these observational 
studies alone do not prove a causal effect, although they are strongly 
suggestive. This research was also conducted in populations where a 
large proportion of HIV-positive individuals are men who have sex with 
men (MSM), and the generalisability of the findings to heterosexual 
populations may be questioned. However, the recently terminated 
HPTN 052 study indeed demonstrates that ART reduces the risk of HIV 
transmission in serodiscordant predominantly heterosexual couples.
HPTN 052 was an international study that began enrolling in 2005. A 
total of 1 763 HIV-positive people in serodiscordant relationships and 
with CD4 counts from 350 to 550 cells/µl were randomised to either 
receive ART immediately (immediate group) or when their CD4 count 
fell below 250 cells/µl (delayed group). A total of 39 HIV infections 
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occurred, and genetic analysis demonstrated that most transmission 
was between partners enrolled in the trial. Only one HIV transmission 
took place from HIV-positive to HIV-negative partner in the immedi-
ate group versus 27 in the delayed group (hazard ratio (HR) 0.04; 95% 
confidence interval (CI) 0.01 - 0.27; p<0.001).12 The study was due to 
complete in April 2015, but the Data Safety Monitoring Board termi-
nated it in May 2011 because of the highly significant results.
An additional important finding from HPTN 052 is that patients in the 
immediate initiation arm had fewer treatment endpoints, defined as 
first serious HIV-related clinical event or death (HR 0.59; 95% CI 0.40 
- 0.88; p=0.01). The difference was driven by the fact that three par-
ticipants in the immediate arm versus 17 in the delayed arm developed 
extrapulmonary TB (p=0.002). However, given the wide CI and the fact 
that the treatment initiation threshold was 250 cells/µl (not 350 cells/
µl), this is not conclusive evidence of the benefit of early treatment to 
the patient.
Existing research suggests that a test-and-treat approach is likely to re-
duce HIV incidence. It is of course not a panacea: test-and-treat will sel-
dom identify patients with primary HIV infection and therefore will not 
eliminate transmissions during primary HIV infection. Infections due to 
virological failure should also be expected, and there is the inevitable 
decline in efficacy when moving from trial conditions to programmes 
serving entire populations. Nevertheless, combined with scaled-up 
male medical circumcisions and condom distribution, we now have a 
formidable arsenal for reducing sexually transmitted HIV infections.
A further public health benefit of test-and-treat is the effect on the 
TB epidemic. Observational data also show a correlation between ART 
scale-up and reduced TB incidence. For example, one study in Masi-
phumelele township in Cape Town found that pre-ART adult TB noti-
fications increased by an average of 212 cases per 100 000 people per 
year, while post-HAART, adult cases decreased by 116 per 100 000 per 
year.13,14
WHAT DOES THIS MEAN FOR GUIDELINES?
While ‘test-and-treat’ policies might still be a few years away, it is per-
plexing that the South African treatment guidelines still use an ART 
initiation threshold of 200 cells/µl except for pregnant women and 
people with TB (in which case 350 cells/µl is the initiation thresh-
old). This is not a minor issue. A study by Médecins Sans Frontières 
of a Lesotho cohort found that the 639 patients who initiated above 
200 cells/µl were 68% less likely to die and 39% less likely to be lost 
to follow-up than patients who initiated below 200 cells/µl. Only 56 
patients were pregnant and 66 had TB, and thus would have been 
started on treatment according to the South African guidelines.15 
By failing to update our guidelines to the WHO standard, i.e. offer-
ing ART to all patients at first CD4 count below 350 cells/µl, we are 
probably losing lives.*
WHAT ABOUT COSTS?
Costing and operational issues are major concerns in implementing a 
‘test-and-treat’ strategy on a large scale. One analysis presented at the 
International AIDS Conference in 2010 estimates the cost of using ART 
for prevention in South Africa. This analysis concluded that expanding 
ART to all CD4 levels, beyond the recommended WHO threshold of 350 
cells/µl, would add $700 million to the cost of the programme, but that 
this would prevent 681 000 new infections over time, and consequently 
allow the cost of the programme to break even by 2022.16
Another analysis by the Health Economics and Epidemiology Research 
Office (HERO) has examined the cost of ART using the WHO guide-
lines compared with a CD4 initiation of 200 cells/µl (South Africa’s old 
guidelines). The cost of first-line tenofovir-based regimens is estimated 
to be R4 320 per patient for the first 6 months of treatment followed 
by R6 126 per patient per year.17 The ASSA2008 model estimates that 
there are 5.6 million people with HIV and 1.2 million on treatment.18 If 
hypothetically it were possible to initiate 1 million people on ART with 
CD4 counts >350 cells/µl who pass through the HCT programme over 
the next year as part of a test-and-treat programme at an average of 
R7 000 per patient for the first year, the additional cost of ART would be 
R7 billion – a substantial burden on the state’s finances. However there 
are also potential cost savings due to reduced HIV infections and possi-
bly reduced opportunistic infections. The potential of reducing the cost 
of treatment by lowering ART prices, task-shifting, and the potential for 
the private sector to absorb a greater part of the cost of treatment than 
it currently does should also be considered. 
The HERO study suggests that if task-shifting were implemented and 
optimal reference prices were paid for ART regimens, the WHO 350 
cells/µl initiation threshold including tenofovir-based regimens would 
cost less to implement than using the old 200 cells/µl threshold with 
stavudine (without task-shifting and optimal reference prices). Analy-
ses like this demonstrate that it is not necessarily guideline improve-
ments that stand in the way of making programmes more affordable, 
but rather sub-optimal drug prices and programme design and staffing 
plans. In this light, it is possible that ‘test-and-treat’ approaches could 
be made highly cost-effective, and analyses of the costs and benefits of 
such an approach are clearly needed.
CONCLUSION
While we do not yet have sufficient data to change guidelines to adopt 
test-and-treat, there are sufficient data to support preliminary pro-
grammes to research this approach. The HPTN 052 results suggest that 
‘test-and-treat’ may present an opportunity to reduce HIV incidence in 
South Africa. Nationally, we need to consider piloting in some health 
facilities the offer of ART to HIV-positive people in serodiscordant rela-
tionships, heterosexual or homosexual, irrespective of CD4 count. Such 
an operational research cohort would help us estimate the cost of a 
test-and-treat approach and identify its practical challenges and op-
portunities.
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